Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Norcyclobenzaprine (also known as desmethylcyclobenzaprine) is a major active metabolite of cyclobenzaprine, a muscle relaxant commonly marketed under the brand name Flexeril. Norcyclobenzaprine shares structural similarity with its parent compound and is formed in the body through demethylation. Both cyclobenzaprine and norcyclobenzaprine are potent antagonists of the serotonin 2a receptor. While cyclobenzaprine is used clinically to treat muscle spasms associated with acute musculoskeletal conditions, norcyclobenzaprine itself is not marketed as an independent pharmaceutical product but may contribute to the pharmacological effects and side effect profile of cyclobenzaprine therapy[9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on norcyclobenzaprine.